Aurinia Pharmaceuticals (AUPH) announced that independent proxy advisor Glass, Lewis & Co. has recommended that Aurinia shareholders vote “for” all proposals put forth by the Board of Directors at the company’s 2025 Annual General Meeting on Thursday, May 15, at 12:00 p.m., Eastern Time. Glass Lewis supports all of the proposals in the company’s proxy statement and management information circular, including approving the six director nominees, the proposed auditor, the non-binding advisory vote on the company’s approach to executive compensation, and an amendment to the Company’s Equity Incentive Plan. Shareholders of record at the close of business on April 12 are entitled to notice of, and to vote on the proposals.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting
- Independent advisor recommends Aurinia shareholders to vote FOR board proposals
- AUPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insider Moves: Semtech, BioMarin, Yum!, Tenaya, Aurinia
- Aurinia Pharmaceuticals: Strong Financial Performance and Strategic Positioning Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue